- Bonds Flat as Stock Market Looks for Direction
- IPOs in the City: Prada Vs. Ferragamo
- Sprint's Quarterly Loss Widens, Revenue Falls
- MBIA Swings to Huge Loss of $2.4 Billion
- Ford May Scrap Mercury Rather than Revive It
- HSBC Earnings, Bad Debts Rise
- Morgan Stanley Raises $4 Billion for Infrastructure
- Inflation, Housing Data Lead Busy Economic Week
- Energy Stocks, HSBC Lead Markets Higher
- European Shares Set to Open Mixed
- What's In A Name: Kobe And Eli Up, Roger Down--And Darren?
- Hybrid Backlash: Your Comments On My "Critical" Post
- "Major League Eating: The Game" Now On Wii (And No Calories)
- Market 360: The Best and Worst of the Week for US Equities, Commodities, Currencies, and More
- Your First Move For Monday May 12th

- Web Extra: 3 Trades For Week Ahead

- Surprise Friday: Guess The Guest!

- Lightning Round OT: Fluor, Aqua America and More

- Cramer: AIG Chief Must Go
- The Fast Money Misfires – Friday May 9th

- StemCells files second patent suit vs. Neuralstem
- MTR expects full-year loss of no more than $2M
- MTR Gaming swings to 1Q loss on higher expenses
- Premarket Movers: Encana rises, Cablevision falls
- Valspar 2008 outlook falls short of estimates
- Radian Group 1Q earnings rise on unrealized gains
- Pollo Campero opens franchise in US Wal-Mart store
- Valspar 2Q profit rises 4 percent on sales boost
- IPO Spotlight: Verso Paper takes advantage of rising prices
- China's vehicle sales rise 14 pct in April
BRIDGEWATER, N.J. - Specialty pharmaceutical company Alpharma Inc. said Friday it has revised a first-quarter gain related to the sale of its Active Pharmaceutical Ingredients business upward by $8 million, boosting its quarterly earnings.
Alpharma reported the increased gain of $209.5 million, or $4.85 per share, in its quarterly financial report with the Securities and Exchange Commission on Friday. The company previously reported a first-quarter gain of $201.5 million, or $4.66 per share, on the sale.
As a result, Alpharma's first-quarter earnings per share, including discontinued operations, totaled $3.96, compared with its previous report of $3.77.
Alpharma said the benefit is subject to further adjustments based on the closing net cash balance and working capital of the business.
Alpharma shares dropped 56 cents, or 2.2 percent, to $25.01 in afternoon trading. The stock has traded between $17.55 and $28.67 during the past 52 weeks.


